BofA analyst Joshua Dennerlein downgraded Sabra Health Care to Underperform from Neutral with a price target of $13, down from $15, updating his valuation model after the company’s Q3 results. The analyst states that it is "puzzling" why Sabra would transition a portfolio with healthy coverage to new operators and offer a rent cut. Dennerlein adds that the quarter offered little clarity and opened questions regarding the strength of the company’s lease agreements with its tenants.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SBRA: